Healthcare provider profile · identity verified

Timothy Tran, MD

Internal Medicine · LOS ANGELES, CA · NPI 1922170406

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	695	245
Losartan Potassium	Losartan Potassium	512	185
Amlodipine Besylate	Amlodipine Besylate	405	166
Lisinopril	Lisinopril	289	107
Hydrochlorothiazide	Hydrochlorothiazide	262	96
Rosuvastatin Calcium	Rosuvastatin Calcium	236	100
Atenolol	Atenolol	229	82
Levothyroxine Sodium	Levothyroxine Sodium	228	81
Metformin Hcl	Metformin Hcl	227	90
Glipizide	Glipizide	212	74
Terazosin Hcl	Terazosin Hcl	201	74
Omeprazole	Omeprazole	186	80
Simvastatin	Simvastatin	171	58
Finasteride	Finasteride	164	53
Tamsulosin Hcl	Tamsulosin Hcl	160	57
Metformin Hcl Er	Metformin Hcl	157	58
Metoprolol Tartrate	Metoprolol Tartrate	149	49
Triamcinolone Acetonide	Triamcinolone Acetonide	147	66
Potassium Chloride	Potassium Chloride	141	52
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	126	50
Albuterol Sulfate Hfa	Albuterol Sulfate	122	65
Pradaxa	Dabigatran Etexilate Mesylate	118	39
Gabapentin	Gabapentin	115	50
Allopurinol	Allopurinol	104	37
Alendronate Sodium	Alendronate Sodium	103	42
Famotidine	Famotidine	103	47
Meloxicam	Meloxicam	98	49
Bisoprolol Fumarate	Bisoprolol Fumarate	92	38
Furosemide	Furosemide	91	36
Jardiance	Empagliflozin	90	36
Pantoprazole Sodium	Pantoprazole Sodium	85	37
Tramadol Hcl	Tramadol Hcl	77	23
Fluticasone Propionate	Fluticasone Propionate	76	39
Clopidogrel	Clopidogrel Bisulfate	70	27
Ibuprofen	Ibuprofen	68	26
Alprazolam	Alprazolam	67	17
Mirtazapine	Mirtazapine	65	29
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	56	17
Trazodone Hcl	Trazodone Hcl	56	22
Glipizide-Metformin	Glipizide/Metformin Hcl	54	20
Lovastatin	Lovastatin	54	20
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	54	23
Alvesco	Ciclesonide	52	24
Colchicine	Colchicine	47	23
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	46	12
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	44	44
Carvedilol	Carvedilol	44	19
Hydrocortisone	Hydrocortisone	44	14
Spironolactone	Spironolactone	44	13
Azelastine Hcl	Azelastine Hcl	41	21
Ciclopirox	Ciclopirox	37	19
Ezetimibe	Ezetimibe	36	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	36	12
Humulin N Kwikpen	Insulin Nph Human Isophane	35	13
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	34	34
Eliquis	Apixaban	32	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	31	17
Ozempic	Semaglutide	30	suppressed
Spiriva Respimat	Tiotropium Bromide	30	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	29	11
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	27	27
Azithromycin	Azithromycin	27	26
Benazepril Hcl	Benazepril Hcl	27	suppressed
Gemfibrozil	Gemfibrozil	27	suppressed
Citalopram Hbr	Citalopram Hydrobromide	26	11
Lactulose	Lactulose	26	14
Lorazepam	Lorazepam	26	11
Myrbetriq	Mirabegron	26	12
Duloxetine Hcl	Duloxetine Hcl	25	11
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	25	11
Latanoprost	Latanoprost	25	13
Propranolol Hcl	Propranolol Hcl	23	suppressed
Donepezil Hcl	Donepezil Hcl	22	suppressed
Nitroglycerin	Nitroglycerin	22	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	22	suppressed
Verapamil Er	Verapamil Hcl	22	suppressed
Amoxicillin	Amoxicillin	21	19
Wixela Inhub	Fluticasone Propion/Salmeterol	21	14
Cephalexin	Cephalexin	20	17
Clobetasol Propionate	Clobetasol Propionate	20	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Prednisone	Prednisone	19	14
Sertraline Hcl	Sertraline Hcl	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	17	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	17	suppressed
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Tacrolimus	Tacrolimus	17	13
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	17	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Trospium Chloride	Trospium Chloride	16	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	16	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Metoprolol Succinate	Metoprolol Succinate	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Raloxifene Hcl	Raloxifene Hcl	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Humalog	Insulin Lispro	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Mupirocin	Mupirocin	14	suppressed
Ondansetron Hcl	Ondansetron Hcl	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Breyna	Budesonide/Formoterol Fumarate	13	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	13	suppressed
Humulin N	Insulin Nph Human Isophane	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Ofloxacin	Ofloxacin	13	13
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	12	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	12	12
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Humulin R	Insulin Regular, Human	11	suppressed
Montelukast Sodium	Montelukast Sodium	11	suppressed
Retin-A	Tretinoin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error